A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Clinical trial NCT05664243 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05664243
- Sponsor
- In8bio Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-08
- Primary completion
- 2025-12-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.